Close Menu

Emily Balskus, Ami Bhatt, Dean Lee, Jeffrey Rathmell, Noopur Raje, Cameron Turtle

Feb 12, 2019

Caribou Biosciences has appointed Emily Balskus, Ami Bhatt, Dean Lee, Jeffrey Rathmell, Noopur Raje, and Cameron Turtle to its scientific advisory board. 

Balskus is a professor of chemistry and chemical biology at Harvard University and an associate member of the Broad Institute of Harvard and MIT. Bhatt is an assistant professor of medicine (hematology) and genetics at Stanford University. Lee is a professor of pediatrics at Nationwide Children's Hospital and Ohio State University, and is also the founding director of the joint cellular therapy and cancer immunotherapy program between the Research Institute at Nationwide Children's Hospital and Ohio State University Comprehensive Cancer Center. Rathmell serves as director of the Vanderbilt Center for Immunobiology and as associate director of the Institute of Infection, Immunology and Inflammation at the Vanderbilt University Medical Center. Raje is a professor of Medicine at Harvard Medical School, director of the Center for Multiple Myeloma, and the Rita Kelley Chair in Oncology at the Massachusetts General Hospital Cancer Center. And Turtle is an associate member at Fred Hutchinson Cancer Research Center and an associate professor at the University of Washington.

The new members will join current scientific advisory board members and Caribou cofounders Jennifer Doudna and Martin Jinek.

More Like This

May 23, 2019

Nelson Chan

Twist Bioscience has appointed Nelson Chan to its board of directors. Chan has been an advisor to Twist for the last 18 months for the firm's DNA data storage business. Chan is also chairman of the board at Synaptics and Adesto, as well as executive chairman of HZO. He previously served as CEO of Magellan and has also held various senior management roles at SanDisk Corporation. Chan will replace Paul Conley, managing director of Paladin Capital Group, who has served on Twist's board since 2013.

May 22, 2019

David Fenstermacher

DNAnexus has hired David Fenstermacher as VP of precision medicine and data services. Fenstermacher will supervise the vendor's data management products for precision health and drug discovery applications. Fenstermacher, a molecular biologist and informatician, previously served as VP of R&D bioinformatics at MedImmune. He also had been chief research information officer at Virginia Commonwealth University and was the founding chair of the Department of Biomedical Informatics at the H. Lee Moffitt Cancer Center.

May 21, 2019

Sangeeta Bhorade

Veracyte has hired Sangeeta Bhorade as medical director of pulmonology to lead medical affairs for the firm's pulmonology products. Bhorade joins Veracyte from Northwestern University Feinberg School of Medicine, where she served as professor of medicine and medical director of the lung transplant program. Prior to Northwestern, Bhorade served as medical director of the lung transplant program at the University of Chicago Medical Center. She has also served as associate medical director of lung transplant at Loyola University Chicago.

May 15, 2019

Norman Winarsky

Predictive analytics firm Interpreta has hired Norman Winarsky as vice president of artificial intelligence and natural-language analytics. In that capacity, Winarsky will supervise development of voice, image, and natural-language interpretation technologies for the company. Winarsky, a former president of SRI Ventures, cofounded the Siri voice assistant.

May 13, 2019

Jan Groen

Novigenix has appointed Jan Groen as the firm's CEO and member of its board of directors. Prior to Novigenix, Groen served as president and CEO of MDxHealth. Groen is co-founder of ViroClinics, founder and CEO of DxOrange, and currently serves on the board of Angle and Destina Genomics. 

May 10, 2019

Nancy White

Inagene Diagnostics has appointed Nancy White as its CEO. White joined the firm in January as VP of sales and marketing. Prior to Inagene, White held several management roles at Novartis and Novartis Oncology from 2008 to 2018, including VP and franchise head, retina, region LACan; as well as global team lead, advancing commercial excellence, innovative customer models. Before Novartis, White served in multiple roles at Allergan from 2003 to 2008. Prior to Allergan, she held roles at Eli Lilly from 1999 to 2003. 

May 09, 2019

Sun Kim

Centogene has appointed Sun Kim as its chief strategy and investor relations officer. Prior to Centogene, Kim served as head of corporate strategy at Shire Pharmaceuticals. Before Shire, Kim worked at Alcon for six years, where he served in multiple roles including head of strategy and general manager of Alcon Singapore.

May 08, 2019

Christian Meisel

Molecular Health has appointed Christian Meisel as its chief medical officer. Prior to Molecular Health, Meisel worked at Roche, where he served in multiple leadership roles including global head of its personalized healthcare platform, acting global head of translational medicine oncology, and global head of biomarkers and translational R&D innovation. 

May 07, 2019

David Parker, Mike Evans

David Parker, a general partner in Ampersand Capital Partners, and Mike Evans, operating partner at Ampersand, have joined the board of Dutch firm Genome Diagnostics, which said this week that Ampersand invested an undisclosed amount in the firm. Ampersand, as a result, became minority shareholders in GenDx. 

May 02, 2019

Sue Paish

Contextual Genomics has appointed Sue Paish as the chair of its board of directors. She will be replacing Chris Wagner, who is stepping down but will remain a director. Paish is currently CEO of the Digital Technology Super Cluster, chair of the board of directors of the Business Council of British Columbia, and a director of CORIX Group. Paish joined Contextual Genomics in 2018 and previously served as president and CEO of LifeLabs Medical Laboratory Services. Prior to LifeLabs, Paish served as CEO of Pharmasave and managing partner of Fasken. 

Apr 30, 2019

Brent Satterfield

Co-Diagnostics has announced that Brent Satterfield, one of the firm's directors, has resigned from its board. He will remain as the firm's CSO. 

Apr 30, 2019

Jimmy Lin

Freenome has appointed Cheng-Ho Jimmy Lin, as its chief scientific officer, with responsibilities for scientific strategy, research operations, and growing the company’s scientific team. Prior to joining the private sector, Lin led the intramural clinical genomics program at the National Cancer Institute at the National Institutes of Health. At Johns Hopkins and Washington University in St Louis, he also spearheaded the computational analyses of exome sequencing studies in multiple cancer types.

Lin's most recent role was CSO for oncology at Natera, where he drove the development and launch of that firm's blood-based assays for cancer monitoring residual disease detection. He holds an MD and PhD in cellular and molecular medicine and a Masters in health sciences in bioinformatics from Johns Hopkins School of Medicine.

Apr 30, 2019

Ron McGrath

Inscripta has appointed Ron McGrath as its CFO. McGrath has held various leadership and financial roles in the biotechnology and information technology industries. Prior to Inscripta, McGrath served as VP of finance at Illumina. He also served as chief of staff for the company's operations. Before joining Illumina, McGrath held financial leadership roles at Memec and DJ Orthopedics.

Apr 25, 2019

Alfred Bowie Jr.

Veracyte has named Alfred Bowie Jr. as vice president of corporate and business development where he will lead the company's strategic planning process. Previously, Bowie led strategic planning, corporate development and competitive intelligence at Foundation Medicine, a Roche subsidiary, and served in corporate and business development positions at Tecan Group and Danaher Corporation. He has also worked in management consulting at the Boston Consulting Group.

Apr 25, 2019

Darrin Crisitello, Nigel Beard, Marcel Roche

Mission Bio has appointed three members to its executive team, including Darrin Crisitello as chief commercial officer, Nigel Beard as senior VP of research and development, and Marcel Roche as senior VP of finance and administration. Prior to Mission Bio, Crisitello led global clinical teams at Color Genomics and Natera. Crisitello has over 19 years of experience in commercial leadership and business development in next-generation sequencing, microfluidics, artificial intelligence, and machine learning, Beard has launched more than 50 products and has been an inventor on more than 40 patents. He has previously worked at firms such as GlaxoSmithKline and Life Technologies, as well as startups like Feetz. Prior to Mission Bio, Roche served as VP of finance at Achaogen and at Guardant Health.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.